News

The State of Play for Cost-effectiveness Thresholds

Tuesday, 28 June 2022

In a new paper led by OHE, an international team of co-authors considers the evidence for supply-side cost-effectiveness thresholds, providing a set of recommendations for policymakers. In this blog post, Chris Sampson provides an overview of the findings and key messages.

Read more »

Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office

Wednesday, 22 June 2022

Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector think tank has made three improvements to its methodology. We review these updates, assess their impact, and highlight the key remaining limitations of the modelling approach, concluding that policymakers should still exercise considerable caution in relying on its predictions.

Read more »

Sleepio: Lessons from the Frontier of Digital Therapeutics

Tuesday, 31 May 2022

The National Institute for Health and Care Excellence (NICE) recently issued its first guidance for a digital therapeutic. NICE recommends the use of Sleepio for treating insomnia symptoms in primary care. OHE played a vital role in developing the evidence to support the guidance. In this blog post, Chris Sampson shares the story of how we got there, and some lessons from the experience.

Read more »

Pages